WOODBRIDGE, ON, Aug. 23, 2012 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular
disease and overall health, is pleased to announce that the company
will be exhibiting at the European Society of Cardiology (ESC) Congress
2012 in Munich, GermanyAugust 25-29, 2012, Hall A2 Booth #B440. The
ESC Congress is the largest meeting of Cardiologists in Europe and a
forum for the latest research in cardiovascular disease, both clinical
and experimental. It is a renowned Medical Trade Show that attracts
delegates from all over the world.
The scientific data demonstrating the superiority of VASCAZEN's formulation recently presented at the 17th World Congress on Heart Disease - Annual Scientific Sessions has been
expanded and these additional findings will be presented at the ESC
Congress. The presentation will take place on Monday August 27, 2012 at
16:30 in Tripoli Village 1. The study, entitled The highly purified EPA:DHA 6:1 product evokes potent
endothelium-dependent relaxations of porcine coronary artery rings via
the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of eNOS,was authored by F. Zgheel, M. Alhosin, C. Auger and V.B. Schini-Kerth
and conducted at the University of Strasbourg, Illkirch and France.
"Exhibiting at the ESC Congress is an important step in the introduction
of VASCAZENTM to the European market" stated Dr. George Jackowski, Chairman and Chief
Scientific Officer of Pivotal Therapeutics. "We are absolutely
delighted that the Scientific Study presented last month in Toronto,
demonstrating the superiority of VASCAZEN's unique formulation, was chosen for presentation to this international
audience. We are eager to share these findings, especially given the
importance to patients with Coronary Heart Disease."
About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF); (CNSX: PVO) specialty
pharmaceutical company with a focus on cardiovascular disease and
overall health. Pivotal Therapeutics' lead product VASCAZENTM is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications.
VASCAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected
by a series of both issued and pending US and foreign patents and
commercialized as a prescription only Medical Food in the U.S. This
unique formulation will provide the cornerstone upon which a family of
cutting edge combination products, with efficacy across a broad
spectrum of cardiac care, will be commercialized.
OMAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation
commercialized for sale and distribution in Canada for the maintenance
of good health through elevating Omega-3 fatty acid levels. The unique
formulation and dosage will be available to patients and consumers who
realize the health benefits of Omega-3 supplementation with a quality
The information contained in this document is as of August 23, 2012.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as "will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal's inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance; risks
relating to the Company's ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.